Serenex Inc.
This article was originally published in Start Up
Executive Summary
Serenex has built a high-throughput affinity displacement discovery platform that enhances compound-target identification and helps spot likely sources of toxicity very early in the discovery process. The company is applying its technology for a growing list of partners, but also aims to build a drug discovery business of its own.
You may also be interested in...
Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire
Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.